Second phase III study of ALLN-177 enteric hyperoxaluria

Trial Profile

Second phase III study of ALLN-177 enteric hyperoxaluria

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs ALLN 177 (Primary)
  • Indications Hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms URIROX-2
  • Sponsors Allena Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2018 New trial record
    • 06 Mar 2018 According to an Allena Pharmaceuticals media release, the company expects to initiate URIROX-2 in the second half of 2018.
    • 06 Mar 2018 According to an Allena Pharmaceuticals media release, the company is working with the FDA to finalize the design of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top